BofA analyst Michael Ryskin raised the firm’s price target on Idexx Laboratories (IDXX) to $535 from $475 and keeps a Neutral rating on the shares after the company reported a “strong” Q4 and initial FY25 guidance came in ahead of expectations. However, the firm sees “relatively little further upside risk to estimates, barring a broader market upturn,” so it reiterates a Neutral rating.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target raised to $520 from $481 at Barclays
- IDEXX Laboratories Reports Strong 2024 Financial Results
- IDEXX Labs Earnings Call Highlights Growth and Innovation
- Early notable gainers among liquid option names on February 3rd
- Morning Movers: Tyson Foods jumps following first quarter results